Regulatory Approval

Co-Diagnostics is developing a point-of-care Ebola test promising 30-minute results. But can it navigate regulatory hurdles and reach the front lines in time?

A novel probiotic, sourced from an elite athlete's gut, has navigated the FDA's complex regulatory maze, signaling a major shift for the entire industry.

With dual FDA clearances secured, Rhythm AI appoints serial acquirer Mike Dineen as CEO, signaling a strategic pivot from innovation to market conquest.

Pluri is moving its advanced cell-expansion tech from the lab to the lucrative U.S. aesthetics market. Is this a savvy commercial pivot or a risky gamble?

ChinaAMC is industrializing its operations with a vast AI system, from investment research to 'digital confidants.' CEO Li Yimei's blueprint is clear: automate the machine, but never the trust.

A new alliance of tech, design, and shipbuilding aims to deliver autonomous, low-signature vessels, promising to reshape both naval power and logistics.

A new study reveals molecular and AI-imaging tests provide distinct clues for Parkinson's, championing a dual-biomarker approach for earlier, more accurate diagnosis.

A new alliance between Solid Biosciences and NanoMosaic pairs advanced delivery with precision analytics, aiming to de-risk development and redefine success.

AbbVie secures EU approval for AQUIPTA as an acute migraine therapy, creating a dual-use drug that challenges rivals and reshapes patient care strategy.

As Nanobiotix joins Europe's tech elite, its nanotech cancer therapy gains a powerful spotlight, signaling a new era for physics-based medicine.

NatGold Digital enters the EU with a regulated token for unmined gold, a high-stakes test for its non-extractive model and Europe's new MiCA framework.

Industrial Acceptance Corp.'s massive data breach reveals a year-long delay in notifying victims, raising critical questions about corporate liability and trust.

Haisco's Cipepofol gains US FDA approval, challenging Propofol with enhanced safety and signaling a new era of Chinese pharmaceutical innovation.

SurGenTec's FDA clearance for its ION-C™ system, now compatible with Medtronic navigation, signals a new era of precision in cervical spine surgery.

Landmark Phase 3 trial shows TECVAYLI dramatically improves survival in early relapse, poised to become a new standard of care for multiple myeloma.

A massive new transmission project, PowerOn Midwest, aims to inject billions into Minnesota's economy and unlock vast renewable energy potential.

A new AI platform using smartwatches just got FDA's Breakthrough nod, promising to predict heart failure crises before they happen from home.

United Texas Bank secured a rare national charter, positioning it with AI-powered tech to bridge traditional banking with stablecoins and digital assets.

Cumberland Pharmaceuticals and SciClone launch Vibativ in China, offering a new defense against deadly, drug-resistant bacteria in a high-stakes market.

A novel oncolytic bacteria therapy gains key approvals in the US and China, showcasing a new global development model enabled by CDMO Porton Advanced.